Tags

Type your tag names separated by a space and hit enter

Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
Eur Urol. 2009 Mar; 55(3):640-7.EU

Abstract

BACKGROUND

Local occurrence of prostate cancer (PCa) after external beam radiation (EBRT) may benefit from definitive local therapy.

OBJECTIVE

To evaluate the safety and efficacy of salvage high-intensity focal ultrasound (HIFU) in local PCa recurrence after EBRT and to determine prognostic factors for optimal patient selection.

DESIGN, SETTING, AND PARTICIPANTS

Between 1995 and 2006, patients with a local PCa recurrence after EBRT were retrospectively included.

INTERVENTION

All patients received salvage HIFU with the Ablatherm device.

MEASUREMENTS

Prognostic factors (pre-EBRT risk group, androgen-deprivation [AD] use, pre-HIFU prostate-specific antigen [PSA], Gleason score and positive biopsy percentage) were studied in univariate and multivariate analyses. Progression was defined as positive biopsy and/or last PSA > nadir + 2 ng/ml and/or adjuvant therapy introduction. All complications were recorded.

RESULTS AND LIMITATIONS

Some 194 HIFU sessions for 167 patients were performed. Local cancer control was achieved with negative biopsy results in 122 (73%) patients. The median PSA nadir was 0.19 ng/ml. The mean follow-up period was 18.1 mo (range: 3-121 mo). Seventy-four patients required no hormone therapy. The actuarial 5-yr overall survival rate was 84%. The actuarial 3-yr progression-free survival rate was significantly lower in three circumstances: (1) worsening of the pre-EBRT stage with 53%, 42%, and 25% for low-, intermediate-, and high-risk patients, respectively, (2) increase in the pre-HIFU PSA, and (3) use of AD during PCa management. In multivariate analyses, the risk ratio for intermediate- and high-risk patients were 1.32 and 1.96, respectively. The risk ratio was 2.8 if patients had received AD. No rectal complications were observed. Urinary incontinence accounted for 49.5% of the urinary sphincter implantations required in 11% of patients. This is a retrospective study in which the role of the PSA doubling time and the time until recurrence was not evaluated.

CONCLUSIONS

Salvage HIFU is a curative treatment option for local relapse after EBRT with acceptable morbidity. Careful patient selection is imperative depending upon the aforementioned prognostic factors.

Authors+Show Affiliations

Urology Department, Val d'Ouest Hospital, 39 Chemin de la Vernique, 69130 Ecully, France. gfj-murat@club-internet.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18508188

Citation

Murat, Francois-Joseph, et al. "Mid-term Results Demonstrate Salvage High-intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer." European Urology, vol. 55, no. 3, 2009, pp. 640-7.
Murat FJ, Poissonnier L, Rabilloud M, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol. 2009;55(3):640-7.
Murat, F. J., Poissonnier, L., Rabilloud, M., Belot, A., Bouvier, R., Rouviere, O., Chapelon, J. Y., & Gelet, A. (2009). Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. European Urology, 55(3), 640-7. https://doi.org/10.1016/j.eururo.2008.04.091
Murat FJ, et al. Mid-term Results Demonstrate Salvage High-intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer. Eur Urol. 2009;55(3):640-7. PubMed PMID: 18508188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. AU - Murat,Francois-Joseph, AU - Poissonnier,Laura, AU - Rabilloud,Muriel, AU - Belot,Aurélien, AU - Bouvier,Raymonde, AU - Rouviere,Olivier, AU - Chapelon,Jean-Yves, AU - Gelet,Albert, Y1 - 2008/05/09/ PY - 2008/01/05/received PY - 2008/04/23/accepted PY - 2008/5/30/pubmed PY - 2009/10/24/medline PY - 2008/5/30/entrez SP - 640 EP - 7 JF - European urology JO - Eur Urol VL - 55 IS - 3 N2 - BACKGROUND: Local occurrence of prostate cancer (PCa) after external beam radiation (EBRT) may benefit from definitive local therapy. OBJECTIVE: To evaluate the safety and efficacy of salvage high-intensity focal ultrasound (HIFU) in local PCa recurrence after EBRT and to determine prognostic factors for optimal patient selection. DESIGN, SETTING, AND PARTICIPANTS: Between 1995 and 2006, patients with a local PCa recurrence after EBRT were retrospectively included. INTERVENTION: All patients received salvage HIFU with the Ablatherm device. MEASUREMENTS: Prognostic factors (pre-EBRT risk group, androgen-deprivation [AD] use, pre-HIFU prostate-specific antigen [PSA], Gleason score and positive biopsy percentage) were studied in univariate and multivariate analyses. Progression was defined as positive biopsy and/or last PSA > nadir + 2 ng/ml and/or adjuvant therapy introduction. All complications were recorded. RESULTS AND LIMITATIONS: Some 194 HIFU sessions for 167 patients were performed. Local cancer control was achieved with negative biopsy results in 122 (73%) patients. The median PSA nadir was 0.19 ng/ml. The mean follow-up period was 18.1 mo (range: 3-121 mo). Seventy-four patients required no hormone therapy. The actuarial 5-yr overall survival rate was 84%. The actuarial 3-yr progression-free survival rate was significantly lower in three circumstances: (1) worsening of the pre-EBRT stage with 53%, 42%, and 25% for low-, intermediate-, and high-risk patients, respectively, (2) increase in the pre-HIFU PSA, and (3) use of AD during PCa management. In multivariate analyses, the risk ratio for intermediate- and high-risk patients were 1.32 and 1.96, respectively. The risk ratio was 2.8 if patients had received AD. No rectal complications were observed. Urinary incontinence accounted for 49.5% of the urinary sphincter implantations required in 11% of patients. This is a retrospective study in which the role of the PSA doubling time and the time until recurrence was not evaluated. CONCLUSIONS: Salvage HIFU is a curative treatment option for local relapse after EBRT with acceptable morbidity. Careful patient selection is imperative depending upon the aforementioned prognostic factors. SN - 1873-7560 UR - https://www.unboundmedicine.com/medline/citation/18508188/Mid_term_results_demonstrate_salvage_high_intensity_focused_ultrasound__HIFU__as_an_effective_and_acceptably_morbid_salvage_treatment_option_for_locally_radiorecurrent_prostate_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(08)00542-3 DB - PRIME DP - Unbound Medicine ER -